NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense failed to regain compliance with Nasdaq's $35 million minimum market value of listed securities requirement by the September 29 deadline and faces delisting unless a Nasdaq Hearings Panel grants an appeal and up to 180 additional days. The company regained compliance with the separate $1.00 minimum bid-price rule after a 1-for-20 reverse split, with shares closing at or above $1 for 10 consecutive business days through September 28. Trading in NRSN and NRSNW is expected to continue during the appeal, but continued listing remains uncertain despite ongoing Phase 3 PARAGON trial preparations for PrimeC in ALS.

Analysis

NRSN’s remaining listing deficiency is fundamentally a capitalization-and-financing problem, not a technical bid-price issue. The reverse split restored nominal price compliance but does not create investable market value; maintaining a $35 million equity value likely requires either sustained clinical/strategic re-rating or new capital, with the latter dilutive and potentially self-defeating if issuance pressure offsets the valuation threshold. A hearing stay can preserve Nasdaq access for several months, but it also creates a predictable window for financing or corporate-action announcements rather than resolving the underlying constraint.

Near term, the stock may experience a mechanical relief bounce if the appeal is accepted, particularly given post-split retail float dynamics, but liquidity should deteriorate as institutional screens and market-maker risk limits increasingly discount delisting probability. Over 1-3 months, the relevant catalyst is disclosure of a credible compliance plan—cash runway, financing size/terms, partnership economics, or a transaction—not generic trial-preparation language. A discounted equity raise, warrant repricing, or ATM program would likely pressure both NRSN and NRSNW; warrants are especially exposed because a listing loss materially reduces liquidity and exercise economics.

The contrarian point is that Nasdaq relief itself has limited fundamental value: a 180-day exception only extends the time in which the company must fund pivotal development. The upside case requires independently verifiable evidence that financing can be obtained without severe dilution, or that a strategic counterparty assigns material value to PrimeC before a financing. Falsify the bearish liquidity thesis with market value sustainably above $35 million absent unusual one-day volume, a disclosed runway extending through major clinical milestones, and financing priced near market rather than at a steep discount.

Key Decisions for Investors

• Avoid initiating long NRSN solely on a hearings-panel stay; treat any appeal-related rally over the next days/weeks as event-driven liquidity rather than a durable re-rating unless management discloses cash runway and a specific path to maintain MVLS.
• For accounts able to borrow and tolerate micro-cap execution risk, consider a small short NRSN only after an appeal-driven spike and confirmation of no strategic financing/partner announcement; target a 25-40% decline over 1-3 months on dilution or listing-risk repricing, with a hard stop on a credible partnership, non-dilutive funding, or sustained $35 million-plus market value.
• Avoid NRSNW despite apparent optionality: warrants combine dilution risk, potential delisting-driven liquidity impairment, and uncertain financing terms. Reassess only if the company discloses a funded pivotal-trial plan and the warrant exercise terms remain economically relevant.
• No material read-through to NDAQ: isolated Capital Market compliance events are immaterial to exchange revenue and do not support a trade. Monitor only if a broader biotech delisting wave emerges alongside materially weaker small-cap issuance volumes.